Urinary Acetaminophen Metabolites and Clinical Outcomes in Extremely Premature Infants

Extremely premature infants are treated with acetaminophen (APAP) for pain and patent ductus arteriosus. High doses of APAP in adults are toxic, and a recent study found an association between APAP metabolite levels in mothers' breast milk and both bronchopulmonary dysplasia (BPD) and retinopathy of prematurity (ROP) in their premature infants. In this study, we determined levels of APAP metabolites in the urine of infants at high risk for BPD and ROP.Biorepository urine samples from 314 infants <29 weeks' gestation in the multicenter TOLSURF and PROP studies were analyzed by untargeted UHPLC:MS/MS (Metabolon, Inc.). We performed multivariate logistic regression and meta-analysis to examine associations between APAP metabolite levels and clinical outcomes.4-APAP sulfate was the most abundant of eight detected APAP metabolites and was present in 95% of urines. There were high correlations between levels of 4-APAP sulfate and the other APAP metabolites. In longitudinal studies on a subgroup of infants (day 6-56), periods of elevated 4-APAP sulfate occurred in 24/28 infants and were of longer duration (10.5 vs. 4.2 days, <i>p</i> = 0.001) with higher levels (13.3 vs. 5.6, <i>p</i> = 0.01) in infants after transition to enteral from total parenteral nutrition. Episodes of elevated metabolite did not differ by BPD status. On both days 10 and 28 there were no significant associations between levels of APAP metabolites and either BPD or ROP for all infants or for infants exclusively on parenteral or enteral nutrition.In two cohorts of extremely premature infants, levels of urinary APAP metabolites were not associated with increased risk for two adverse clinical outcomes. · Safety of acetaminophen (APAP) in extremely premature infants has not been established.. · The major urinary APAP metabolite was detected in the majority of urine samples.. · No association was found between APAP levels and either bronchopulmonary dysplasia or retinopathy of prematurity..

Authors

Institutions

Publication Details

Journal
American Journal of Perinatology
Published
2025-01-09
DOI
https://doi.org/10.1055/a-2512-9387
Primary Topic
Pregnancy and Medication Impact
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Urinary Acetaminophen Metabolites and Clinical Outcomes in Extremely Premature Infants

Ronald I. Clyman, Ryan D. Hernandez, Miguel Guardado, Cheryl Chapin et al.
American Journal of Perinatology
Pregnancy and Medication Impact
article

Urinary Acetaminophen Metabolites and Clinical Outcomes in Extremely Premature Infants

Ronald I. Clyman, Ryan D. Hernandez, Miguel Guardado, Cheryl Chapin, Azuka Atum, Rebecca Anne Simmons, Dara Torgerson, Samuel I. Parry, Philip L. Ballard
article en

Abstract

Extremely premature infants are treated with acetaminophen (APAP) for pain and patent ductus arteriosus. High doses of APAP in adults are toxic, and a recent study found an association between APAP metabolite levels in mothers' breast milk and both bronchopulmonary dysplasia (BPD) and retinopathy of prematurity (ROP) in their premature infants. In this study, we determined levels of APAP metabolites in the urine of infants at high risk for BPD and ROP.Biorepository urine samples from 314 infants <29 weeks' gestation in the multicenter TOLSURF and PROP studies were analyzed by untargeted UHPLC:MS/MS (Metabolon, Inc.). We performed multivariate logistic regression and meta-analysis to examine associations between APAP metabolite levels and clinical outcomes.4-APAP sulfate was the most abundant of eight detected APAP metabolites and was present in 95% of urines. There were high correlations between levels of 4-APAP sulfate and the other APAP metabolites. In longitudinal studies on a subgroup of infants (day 6-56), periods of elevated 4-APAP sulfate occurred in 24/28 infants and were of longer duration (10.5 vs. 4.2 days, <i>p</i> = 0.001) with higher levels (13.3 vs. 5.6, <i>p</i> = 0.01) in infants after transition to enteral from total parenteral nutrition. Episodes of elevated metabolite did not differ by BPD status. On both days 10 and 28 there were no significant associations between levels of APAP metabolites and either BPD or ROP for all infants or for infants exclusively on parenteral or enteral nutrition.In two cohorts of extremely premature infants, levels of urinary APAP metabolites were not associated with increased risk for two adverse clinical outcomes. · Safety of acetaminophen (APAP) in extremely premature infants has not been established.. · The major urinary APAP metabolite was detected in the majority of urine samples.. · No association was found between APAP levels and either bronchopulmonary dysplasia or retinopathy of prematurity..

American Journal of PerinatologyVol. 42(12)
Children's Hospital of Philadelphia (US), University of California, San Francisco (US), Parnassia Groep (NL), University of California San Francisco Medical Center (US), University of San Francisco (US), University of Pennsylvania (US)
March of Dimes Foundation, University of Pennsylvania, National Heart and Lung Institute, National Institutes of Health, University of California, San Francisco
Zero hunger, Good health and well-being
Openalex Percentile: Top 99%
Pregnancy and Medication Impact
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.